London: GSK plc has announced the US Food and Drug Administration (FDA) has accepted for review a Biologics License ...
The US Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for belantamab ...
Resubmission addresses questions raised in January 2024 Complete Response Letter F8 formulation intended to replace EGRIFTA SV® with simplified dosing for the treatment of excess abdominal fat in ...
US FDA accepts for review GSK’s Blenrep combinations for the treatment of relapsed/refractory multiple myeloma: London, UK Tuesday, November 26, 2024, 09:00 Hrs [IST] GSK plc an ...
The FDA has accepted for review the resubmitted sBLA for dupilumab for the treatment of chronic spontaneous urticaria.
Levi & Korsinsky, LLP notifies investors in Humacyte, Inc. ("Humacyte, Inc." or the "Company") of a class action securities ...
NEW YORK, NY / ACCESSWIRE / November 25, 2024 / If you suffered a loss on your Humacyte, Inc. (NASDAQ:HUMA) investment and want to learn about a ...
FDA assigns PDUFA target action date of April 29, 2025CLEVELAND, Nov. 12, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ABEO) today ...
FDA accepts BLA resubmission of pz-cel in recessive dystrophic epidermolysis bullosa and sets PDUFA target action date of ...
MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for the third quarter ended September 30, 2024, and ...
Hosted on MSN16h
AbbVie Stock Rises After Leerink Partners Upgrades Its RatingAbbVie’s ABBV shares rose 3.0% on Friday after Leerink Partners analyst, David Risinger, upgraded his rating on the stock ...
Wasting no time after the election, President-elect Donald Trump has started naming his picks for top cabinet and White House positions.Among the high-profile selections are Florida Sen.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback